Menu

HomeConferencesCollectionsCalls for PapersMSF Research EthicsClinical Case ReportingAboutMy Saved Content
Logo

Science Portal

  • My Saved Content
  • Browse All
  • Conferences
  • Collections
  • Calls for Papers
  • MSF Research Ethics
  • Clinical Case Reporting
  • About
English
logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.6333.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Export All Citations
Copyright © Médecins Sans Frontières
v2.1.6333.produseast1
Journal Article
|Research

Impact of introducing human immunodeficiency virus testing, treatment and care in a tuberculosis clinic in rural Kenya

Huerga H, Spillane H, Guerrero W, Odongo A, Varaine FFV
Impact of introducing human immunodeficiency virus testing, treatment and care in a tuberculosis clinic in rural Kenya | Journal Article / Research | MSF Science Portal
Download

Similar Content
Loading...
Loading...
Loading...
Abstract
SETTING
In July 2005, Médecins Sans Frontières and the Ministry of Health, Kenya, implemented an integrated tuberculosis-human immunodeficiency virus (TB-HIV) programme in western Kenya.

OBJECTIVE
To evaluate the impact of an integrated TB-HIV programme on patient care and TB programme outcomes. DESIGN: Retrospective evaluation of three time periods: before (January-June 2005), shortly after (January-June 2006) and medium term after (January-December 2007) the implementation of the integrated programme.

RESULTS
Respectively 79% and 91% of TB patients were HIV tested shortly and at medium term after service integration. The HIV-positive rate varied from 96% before the intervention to respectively 88% (305/347) and 74% (301/405) after. The estimated number of HIV-positive cases was respectively 303, 323 and 331 in the three periods. The proportion of patients receiving cotrimoxazole prophylaxis increased significantly from 47% (142/303) to 94% (303/323) and 86% (285/331, P < 0.05). Before the intervention, 87% (171/197) of the TB-HIV patients would have been missed when initiating antiretroviral treatment, compared to respectively 29% (60/210) and 36% (78/215) after the integration. The TB programme success rate increased from 56% (230/409) to 71% (319/447) in the third period (P < 0.05); however, there was no significant decrease in the default rate: 20% to 22% (P = 0.66) and 18% (P = 0.37).

CONCLUSION
Integrated TB-HIV care has a very positive impact on the management of TB-HIV patients and on TB treatment outcomes.

Countries

Kenya

Subject Area

tuberculosisHIV/AIDS

Languages

English
Published Date
01 May 2010
PubMed ID
20392355
Journal
International Journal of Tuberculosis and Lung Disease
Volume | Issue | Pages
Volume 14, Issue 5, Pages 611-5